HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

New adjuvant therapy for colon cancer: justified hope or commercial hype.

Abstract
This article discusses the role of adjuvant chemotherapy for colon cancer. Six months of adjuvant 5-FU/leucovorin represent the standard of care for resected stage III colon cancer patients. The role of adjuvant chemotherapy for stage II patients remains controversial. Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches.
AuthorsE Galanis, S R Alberts, M J O'Connell
JournalSurgical oncology clinics of North America (Surg Oncol Clin N Am) Vol. 9 Issue 4 Pg. 813-23; discussion 825-6 (Oct 2000) ISSN: 1055-3207 [Print] United States
PMID11008249 (Publication Type: Journal Article, Review)
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Chemotherapy, Adjuvant
  • Colonic Neoplasms (mortality, pathology, therapy)
  • Controlled Clinical Trials as Topic
  • Disease-Free Survival
  • Female
  • Humans
  • Immunotherapy (methods)
  • Male
  • Neoplasm Staging
  • Prognosis
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: